Catalyst Biosciences
Graphic
News

PRESS RELEASES

CATALYST BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM A PHASE 1 CLINICAL TRIAL OF ITS NEXT GENERATION COAGULATION FACTOR VIIA IN PATIENTS WITH HEMOPHILIA A OR B AND PRECLINICAL RESULTS FROM ITS FACTOR IX AND FACTOR XA PROGRAMS

South San Francisco, Calif., June 24, 2015 – Catalyst Biosciences, Inc., a privately held biopharmaceutical company, today announced positive results from a Phase 1 clinical trial of CB 813d/PF-05280602, its next-generation and long- acting coagulation Factor VIIa. Results showed that single doses of CB 813d were well tolerated when administered to hemophilia A and B patients, and there were no instances of antibody response or thrombosis. CB 813d demonstrated pharmacological efficacy as measured by significant shortening of aPTT (activated partial thromboplastin time) and PT (prothrombin time) for up to 48 hours post dosing. The results were presented in a poster session at the International Society on Thrombosis and Haemostasis (ISTH) Meeting being held in Toronto, Canada from June 20 to 25, 2015. More »


CATALYST BIOSCIENCES ANNOUNCES MULTIPLE DATA PRESENTATIONS AT THE 2015 INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS MEETING

South San Francisco, Calif., June 16, 2015 – Catalyst Biosciences, Inc., a privately held biopharmaceutical company, today announced that data from three of its product candidates will be presented at the International Society on Thrombosis and Haemostasis (ISTH) Meeting being held in Toronto, Canada from June 20 to 25, 2015. The presentations, being made by Catalyst and its collaborators, are as follows: More »


TARGACEPT AND CATALYST BIOSCIENCES AMEND DEFINITIVE MERGER AGREEMENT

Winston-Salem, NC and South San Francisco, Calif., May 15, 2015 – Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced that they have entered into an amendment to the definitive agreement to merge the two companies. Targacept and Catalyst previously announced entering into the definitive merger agreement on March 5, 2015. On April 6, 2015, Targacept disclosed the termination, effective June 1, 2015, of the research and license agreement between Catalyst and Wyeth LLC (a wholly owned subsidiary of Pfizer), which governs the development and commercialization of Catalyst's lead product candidate CB 813d/PF-05280602, an engineered Factor VIIa in development for severe hemophilia A and B. The amended agreement between Targacept and Catalyst considers the effect on the combined company of the termination of Catalyst's research and license agreement with Wyeth. More »


TARGACEPT AND CATALYST BIOSCIENCES ENTER DEFINITIVE MERGER AGREEMENT CREATING A PROTEASE-BASED HEMOSTASIS AND ANTI-COMPLEMENT COMPANY

Winston-Salem, NC and South San Francisco, Calif., March 5, 2015 – Targacept, Inc. (NASDAQ: TRGT) and Catalyst Biosciences, Inc., a privately held biopharmaceutical company, jointly announced today that they have entered into a definitive agreement to merge the two companies. The combined entity, to be named Catalyst Biosciences, Inc., is expected to create a financially strong company to harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases. More »


CATALYST BIOSCIENCES AND ISU ABXIS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION BEST-IN-CLASS FACTOR IX THERAPEUTICS

South San Francisco, Calif., October 9, 2013 – Catalyst Biosciences, Inc., focused on discovering and developing novel biopharmaceutical products based on engineered human proteases, and Isu Abxis, an established biologics manufacturing and development company based in Seoul Korea, announced today the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing and the completion of Phase 1 clinical studies designed to establish proof-of-mechanism for the molecule in hemophilia B patients. More »


PFIZER INITIATES PHASE 1 CLINICAL TRIAL FOR FVIIa HEMOPHILIA DRUG CANDIDATE DEVELOPED BY CATALYST BIOSCIENCES

South San Francisco, Calif., January 5, 2012 – Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF–05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences. PF–05280602 has been engineered to provide improved acute and prophylactic treatment for hemophilia A & B patients with inhibitors. The IND filing and initiation of the Phase 1 clinical trial triggered additional milestone payments of $7.0 million payable to Catalyst by Pfizer under the terms of their research and license agreement. More »


CATALYST BIOSCIENCES RECEIVES MILESTONE PAYMENT FROM PFIZER FOR PROGRESS IN LEAD HEMOSTATIS PROGRAM

South San Francisco, Calif., December 16, 2010 – Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders. More »


CATALYST BIOSCIENCES ANNOUNCES AGREEMENT WITH MEDIMMUNE TO DISCOVER AND DEVELOP ENGINEERED PROTEASE THERAPEUTICS

South San Francisco, Calif., July 7, 2009 – Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases. More »


CATALYST BIOSCIENCES AND WYETH PHARAMCEUTICALS ANNOUNCE WORLDWIDE COLLABORATION

Collegeville, PA and South San Francisco, Calif., June 30, 2009 – Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Catalyst Biosciences, Inc. today announced that the two companies have formed an exclusive worldwide collaboration for the discovery, development and commercialization of Factor VIIa products to treat hemophilia and other bleeding conditions.  Total payments under the collaboration, including an upfront payment of $21 million, research funding and milestone payments, could exceed $500 million, exclusive of royalty payments. More »


CATALYST BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD WITH LEADING EXPERTS IN PROTEASE THERAPEUTIC DISCOVERY AND DEVELOPMENT

South San Francisco, Calif., March 24, 2009 – Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has appointed four new members to the company’s Scientific Advisory Board (SAB).  Robert J. Fletterick, Ph.D., David Ginsburg M.D., Guy S. Salvesen, Ph.D., and Gregory Stahl, Ph.D., join initial members Shaun Coughlin, M.D., Ph.D., Charles Craik, Ph.D., and James Wells, Ph.D. More »


CATALYST BIOSCIENCES RAISES $40 MILLION IN SERIES C FINANCING

South San Francisco, Calif., December 3, 2008 – Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, has raised $40.4 million in a Series C financing round.  New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures. More »


CATALYST BIOSCIENCES SELECTS DRUG DEVELOPMENT CANDIDATE IN FACTOR VIIA PROGRAM FOR HEMOPHILIA

South San Francisco, Calif., May 6, 2008 – Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, announced that it has selected CB 813, an improved, second–generation variant of human coagulation factor VIIa, as a development candidate for the treatment of acute bleeding in hemophilia patients. More »


CATALYST BIOSCIENCES AND CENTOCOR RESEARCH & DEVELOPMENT, INC. FORM COLLABORATION TO DISCOVER AND DEVELOP ENGINEERED PROTEASE THERAPEUTICS

South San Francisco, Calif., January 7, 2008 – Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, today announced that it has entered into an exclusive worldwide research and license agreement with Centocor Research & Development, Inc. More»


CATALYST BIOSCIENCES AND WYETH PHARMACEUTICALS SIGN TWO AGREEMENTS FOR NOVEL BIOTHERAPEUTIC PLATFORM OF ENGINEERED PROTEASES

South San Francisco, Calif., January 7, 2007 – Catalyst Biosciences, Inc., today announced that it has signed two research collaboration and license agreements with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), having potential total payments of up to $100 million, exclusive of potential royalty payments. More » 


CATALYST ANNOUNCES APPOINTMENT OF NASSIM USMAN AS CEO

South San Francisco, Calif., February 22, 2006 – Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing novel therapeutic protease products, today announced that Nassim Usman, Ph.D., has been named the Company's Chief Executive Officer. More » 


CATALYST BIOSCIENCES RAISES $30 MILLION SERIES B FINANCING TO ADVANCE THERAPEUTIC PROTEASES

South San Francisco, Calif., February 9, 2006 Catalyst Biosciences, Inc., a privately held biotechnology company focused on engineering and developing novel therapeutic protease producs, today announced it has raised $30 million in its Series B financing. More »


CATALYST BIOSCIENCES LICENSES SEMINAL INTELLECTUAL PROPERTY IN THE FIELD OF PROTEASE THERAPEUTICS

South San Francisco, Calif. and San Diego, CA, July 25, 2005 – Catalyst Biosciences, Inc. and Torrey Pines Institute for Molecular Studies announced today that they have entered into an exclusive worldwide license agreement for Catalyst’s use of the Institute’s seminal intellectual property covering protease engineering, selection and optimization. More »


CATALYST BIOSCIENCES RAISES $10 MILLION IN SERIES A FINANCING

October 28, 2004 – Catalyst Biosciences, Inc., a protein therapeutics company, today announced that it has closed a Series A round of funding at $10.3 million. Sofinnova Ventures led the financing, which also included Burrill and Company, RCT Bioventures and Novartis Venture Fund. Catalyst will use the financing to move its research and development programs through pre–clinical animal models toward clinical development, to expand its technology and infrastructure platform, and to add key personnel and laboratory space. More »